Frequency of mutations in recurrence events of patients with a mutant pTa/T1G1/2 primary bladder tumor.

<p>Frequency of <i>FGFR3</i>, <i>RAS</i>, and <i>PIK3CA</i> mutations is indicated.</p

Primers used for multiplex amplification of <i>HRAS</i>, <i>KRAS</i>, <i>NRAS, PIK3CA</i>, and <i>FGFR3</i>.

<p>Primers used for multiplex amplification of <i>HRAS</i>, <i>KRAS</i>, <i>NRAS, PIK3CA</i>, and <i>FGFR3</i>.</p

Frequencies of individual mutations in primary tumors of 257 patients.

<p>Frequencies of individual mutations in primary tumors of 257 patients.</p

Probes for the detection of <i>HRAS</i>, <i>KRAS</i>, <i>NRAS</i>, <i>PIK3CA</i> and <i>FGFR3</i> mutations.

<p>Probes for the detection of <i>HRAS</i>, <i>KRAS</i>, <i>NRAS</i>, <i>PIK3CA</i> and <i>FGFR3</i> mutations.</p

Frequencies of <i>FGFR3</i>, <i>RAS</i>, <i>PIK3CA</i> mutations and p53 overexpression according to stage and grade.

<p>The correlation of these alterations in primary bladder tumors of 257 patients with stage (A) or grade (B) is indicated by p-values (χ²).</p

Relations between mutations in primary bladder tumors of 257 patients.

<p>Relations between mutations in primary bladder tumors of 257 patients.</p

Combinations of mutations in primary bladder tumors of 257 patients.

<p>Combinations of mutations in primary bladder tumors of 257 patients.</p

RAS-BC mutation assay.

<p>Panel A: wild-type sample, panels B–D: samples with mutations. Position of the interrogated codons, nucleotides and genes is depicted at the bottom.</p

Univariate regression analysis of the ΔCt-values of the 20 single genes predicting node-positive disease at radical cystectomy (n = 139).

<p>Univariate regression analysis of the ΔCt-values of the 20 single genes predicting node-positive disease at radical cystectomy (n = 139).</p

Patient and tumor characteristics of all included patients with lymph node-negative or lymph node-positive disease (n = 139).

<p>The p-value indicates the (non)significant differences between both groups.</p